For example, the inhibition of IL1B and IL6 could ameliorate colitis based on the anti-inflammatory and anti-oxidant activity [51], both of which were involved in the shared up-regulated pathways, including cytokine activity, cytokine-cytokine receptor interaction, graft versus host disease, and type I diabetes mellitus. Here, IL1B is linked to colitis.